Affitech AS

Protein L license granted to U.K. biotech company

Published in Medicine and Law Weekly, July 1st, 2005

Affitech AS announced at the 4th International Congress on Recombinant Antibodies, in Berlin, Germany, that it has granted its first license for production and use of Protein L to a U.K.-based biotechnology company.

According to the agreement, the licensee receives a worldwide non-exclusive research license of the Protein L gene as well as vectors and know-how of Protein L production under the Affitech patent rights for research and preclinical development work. Financial terms of the Agreement were not disclosed.

Protein L is a naturally occurring bacterial protein that binds to the kappa light chain of antibodies without interfering with their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-07-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry